R&D Leaders' Forum Spring 2003
Presentations
If you would like to purchase the documentation (Only available on CD) please email team@phacilitate.co.uk and we will confirm a price with you.
Pre-conference Briefing – April 7, 2003
Delivering a corporate organizational model and strategy to drive the future of pharma R&D
Chairman’s introduction
Defining R&D productivity – which is the best benchmark to use?
Dr John R. Gibson, Senior Vice President, Development, Allergan, Inc
Focus Session 1
How can pharma reorganize to meet R&D productivity targets in the face of an uncertain future?
How has an innovative organizational approach impacted on R&D efficiency and productivity?
Dr John E. Reardon, Senior Vice President, Biology Discovery Research, GlaxoSmithKline
What would be the implications of big pharma leaving research entirely to the biotech sector and academia?
Dr John F. DeLamarter, Director, Science & Discovery, Serono International SA
Focus Session 2
Developing strategies to integrate knowledge and information across the pipeline to optimise the productivity of R&D
Evaluating a source of knowledge for the purpose of improved decision making
Jonathan Woo, PhD, Director, Decision Analysis and Portfolio Management Group, Johnson & Johnson Pharmaceutical Research and Development, LLC
Case Study
Optimizing the role of knowledge transfer in accelerating clinical development
Charles Jaffe, MD, PhD, Director of Medical Informatics, AstraZeneca Pharmaceuticals
Workshop
Efficiency versus effectiveness within the pharma business model – how do you model for effectiveness?
Moderator’s introduction
Dr Wayne A. Rosenkrans, Jr. Global Intelligence Director, US Market Operations and Strategic Planning, AstraZeneca Pharmaceuticals
Examining science strategy
Dick Klavans, President, Center for Research Planning
Competitive technical intelligence applied to pharma R&D
Dr Wayne A. Rosenkrans, Jr. Global Intelligence Director, US Market Operations and Strategic Planning, AstraZeneca Pharmaceuticals
Case study: Scenarioing, continuous strategy, and strategic early warning for discovery
Dr Helen Dowden, Technical Intelligence Manager, AstraZeneca
Mini Wargame – Strategies for your worst nightmare
Moderator:
Dr Wayne A. Rosenkrans, Jr. Global Intelligence Director, US Market Operations and Strategic Planning, AstraZeneca Pharmaceuticals
Main Conference Day 1 – April 8, 2003
Focus Session 1
Optimising portfolio prioritisation and management strategies to improve lead quality and decrease late-stage attrition rates
External perspective
Boeing Phantom Works technology planning & transition process
Miller Adams, Director, Technology Planning & Acquisition, The Boeing Company
Optimizing preclinical phase transition criteria
Dr Anthony Artuso, Senior Director, Decision Analysis, Portfolio Management,
Bristol-Myers Squibb
Case Study
Finding solutions to cultural differences between commercial strategists and the science base in order to improve the quality of your project and portfolio decisions
Dr Ian Triggs, Director, Portfolio, Planning & Business Development, Oncology,
AstraZeneca
Focus Session 2
Maximising the impact of biotechnologies on research productivity and quality
What role should functional genomics play in the fully integrated R&D organization?
Dr Mark Labow, Executive Director, Molecular Genetics, Novartis Pharmaceuticals Corporation
Clarifying the potential challenges and benefits in adopting an integrative systems biology approach
G. Michael Arnold, Former COO, Institute for Systems Biology
Workshop
Implementing strategies to enable the vertical expansion of biotech
Moderator’s introduction
What are the viable alternatives for biotechs in an increasingly competitive marketplace?
Rupert D’Souza, PhD, MBA, Head, Financial Planning & Strategic Analysis, Genentech, Inc
Main Conference Day 2 – April 9, 2003
Achieving breakthrough productivity gain at key stages in the R&D process
External perspective
Auto industry R and D: Moving from Scientific Management to Management by Science
Dr Allen C. Ward, President, Ward Synthesis, Inc
Informatics must enable cross-functional project team collaboration for increased R&D productivity
Darlene J. S. Solomon, PhD, R&D Technology Manager, Life Science and Chemical Analysis Group & Director, Life Science Technologies Laboratory, Agilent Technologies
Focus Session 1
Improving target quality and reducing time-to-trial through the application of integrated predictive technologies
Successfully integrating novel in silico technologies with existing infrastructure to maximise time and cost savings
Dr Lee Babiss, Vice President of Pre-clinical Research & Development, Hoffmann-La Roche, Inc
What value predictive technology? A case study of in silico ADMET modelling
Andrew C. G. Uprichard MD FRCP, Chief Operating Officer, ArQule, Inc
Focus Session 2
Meeting safety requirements whilst reducing the timescales for late-phase development through to regulatory approval
Overcoming the key challenges in designing a large-scale clinical trial
Dr Mike Tansey, Senior Vice President, Medical Development, Chief Medical Officer, Pharmacia Corporation
It's all about patients: How do you find them? What keeps them?
Paula Brown Stafford, Executive Vice President, Scientific Operations, Quintiles Transnational
How will the CTD effect dossiers and documentation assembly?
Cheryl Anderson, RAC, Manager, Global Project Management and Strategic Planning Department, Amgen, Inc
Case Study
Incorporating market information in a predictive trial model to identify the maximum commercial potential of an individual target
Dr Jean-Michel Gries, Director, Clinical Discovery and Human Pharmacology, Aventis Pharmaceuticals
Predictive ADME and toxicity modelling: Integrating into the lead identification strategy
Alan G. E. Wilson, PhD, Senior Director, Pharmacia Corporation
Workshop
Redefining the role of licensing and partnering to maximise their contribution to overall R&D productivity
Analysing the productivity of licensing deals – is Big Pharma seeing a good enough return on its investment in terms of productivity gain?
Mike McCully, Senior Business Development Analyst and Consultant, Recombinant Capital,
